Tyra Biosciences Inc

NASDAQ TYRA

Data sourced from

and

Download Data

Tyra Biosciences Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024: USD 0.00

Tyra Biosciences Inc Revenue Per Share is USD 0.00 for the Trailing 12 Months (TTM) ending March 31, 2024, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Tyra Biosciences Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.00, a 0.00% change year over year.
Tyra Biosciences Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 0.00, a 0.00% change year over year.
Tyra Biosciences Inc Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.00.

NASDAQ: TYRA

Tyra Biosciences Inc

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street, Carlsbad, CA, United States, 92008
Employees	49
Sector	Healthcare
Industry	Biotechnology

Description

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Key trends